BaseHealthTM Adds Illumina CTO To Board Of Directors

Dr. Mostafa Ronaghi brings decades of experience in developing world class genomic and personalized medicine tools to BaseHealth’s board

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
The genomic component of the product is a key differentiator for the company, and Dr. Ronaghi brings the needed expertise to optimize genomic data’s platform value.

Redwood City, CA (PRWEB) May 15, 2014

BaseHealth, the maker of the integrated health management platform GenophenTM, today announced the addition of Dr. Mostafa Ronaghi to the company’s Board of Directors. Dr. Ronaghi is the current Chief Technology Officer of Illumina, Inc., the leader in next-generation sequencing technologies. He is also a serial life sciences entrepreneur with a successful track record in the field of personalized medicine.

BaseHealth’s platform, Genophen, combines genomic data with clinical and behavioral analysis to engage patients with their physicians in a highly-collaborative way. The genomic component of the product is a key differentiator for the company, and Dr. Ronaghi brings the needed expertise to optimize genomic data’s platform value.

“We’re very pleased to welcome Dr. Mostafa Ronaghi to our Board of Directors,” said Hossein Fakhrai-Rad, CEO of BaseHealth. “As we enter the second wave of personal genomics, Dr. Ronaghi’s expertise and perspective will be invaluable to BaseHealth’s growth. His years of experience in life sciences entrepreneurship will be a boon to our company as a whole, and to the product development of Genophen particularly.”

Before joining Illumina as CTO and Senior Vice President, Dr. Ronaghi founded a number of successful life sciences companies, including ParAllele BioScience (acquired by Affymetrix), where he and Dr. Fakhrai-Rad first collaborated, Avantome, and most recently, NextBio (both acquired by Illumina). He also spent 9 years as a principal investigator at the Stanford Genome Technology Center. He received his PhD in Biotechnology from the Royal Institute of Technology.

Dr. Ronaghi is also an inventor of Pyrosequencing, the first next-generation DNA sequencing technology, and the founder of Pyrosequencing AB. He has co-authored over 70 peer-reviewed journal articles and have more than 50 pending and issue patents.

“BaseHealth is pioneering the space of doctor-driven personal genomics,” said Dr. Ronaghi, CTO of Illumina. “The way they integrate personal genomic data with clinical and lifestyle data is unprecedented. I’m looking forward sharing my expertise and contributing to the future direction of what will undoubtedly be a groundbreaking company.”

Dr. Ronaghi joins a renowned group of Board Members including serial Internet and life sciences investor Bobby Yazdani.

The learn more about BaseHealth, visit: http://www.BaseHealth.com.

About BaseHealth

BaseHealth is the maker of Genophen, an integrated health management platform that combines genomic data with clinical and behavioral analysis to engage patients with their physicians in a highly-collaborative way. BaseHealth was founded by a team of leading researchers, computer scientists, healthcare executives, and scientific advisors from Stanford University and the Karolinska Institute in Stockholm, Sweden.

The company began operations in 2011 and is based in Silicon Valley, California. You can learn more about us at: http://www.basehealth.com.

BaseHealth. Be well.


Contact

  • Brittany Smith
    Jones-Dilworth, Inc.
    +1 972-809-6832
    Email